An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Simple 20-meter shuttle run test predicts brain health in overweight kids
Aerobic fitness is often considered one of the best indicators of childhood health. It is also linked to better academic performance, executive function, and larger
January 29, 2024